Which patients with stage II/III dMMR/MSI-H locally advanced rectal cancer would you select for upfront dostarlimab monotherapy?

Which findings would lead you to choose standard multimodality treatment instead of upfront dostarlimab monotherapy for stage II/III dMMR/MSI-H rectal cancer?

• Active autoimmune disease requiring systemic immunosuppression
• Solid organ transplant
• Tumor bleeding requiring urgent local treatment
• cT4 disease
• Threatened circumferential resection margin
• Inability to adhere to close response assessment and surveillance
• Other